| Genome-wide analyses identify KIF5A as a novel ALS gene A Nicolas, KP Kenna, AE Renton, N Ticozzi, F Faghri, R Chia, ... Neuron 97 (6), 1268-1283. e6, 2018 | 578 | 2018 |
| Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis S Bandres‐Ciga, AJ Noyce, G Hemani, A Nicolas, A Calvo, G Mora, ... Annals of neurology 85 (4), 470-481, 2019 | 162 | 2019 |
| ALS clinical trials: do enrolled patients accurately represent the ALS population? A Chiò, A Canosa, S Gallo, S Cammarosano, C Moglia, G Fuda, A Calvo, ... Neurology 77 (15), 1432-1437, 2011 | 107 | 2011 |
| Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials RPA van Eijk, AR Jones, W Sproviero, A Shatunov, PJ Shaw, PN Leigh, ... Neurology 89 (18), 1915-1922, 2017 | 100 | 2017 |
| UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study A Chiò, G Mora, G Restagno, M Brunetti, I Ossola, M Barberis, L Ferrucci, ... Neurobiology of aging 34 (1), 357. e1-357. e5, 2013 | 82 | 2013 |
| Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial V Meininger, A Genge, LH van den Berg, W Robberecht, A Ludolph, ... The Lancet Neurology 16 (3), 208-216, 2017 | 80 | 2017 |
| Whole-blood global DNA methylation is increased in amyotrophic lateral sclerosis independently of age of onset L Tremolizzo, P Messina, E Conti, G Sala, M Cecchi, L Airoldi, R Pastorelli, ... Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 15 (1-2), 98-105, 2014 | 70 | 2014 |
| Association of variants in the SPTLC1 gene with juvenile amyotrophic lateral sclerosis JO Johnson, R Chia, DE Miller, R Li, R Kumaran, Y Abramzon, ... JAMA neurology 78 (10), 1236-1248, 2021 | 54 | 2021 |
| TBK1 is associated with ALS and ALS-FTD in Sardinian patients G Borghero, M Pugliatti, F Marrosu, MG Marrosu, MR Murru, G Floris, ... Neurobiology of aging 43, 180. e1-180. e5, 2016 | 53 | 2016 |
| NADPH oxidase (NOX2) activity is a modifier of survival in ALS G Marrali, F Casale, P Salamone, G Fuda, C Caorsi, A Amoroso, ... Journal of neurology 261, 2178-2183, 2014 | 45 | 2014 |
| Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations V Bonetto, L Pasetto, I Lisi, M Carbonara, R Zangari, E Ferrari, V Punzi, ... Frontiers in immunology 13, 1070379, 2022 | 37 | 2022 |
| Telemedicine for patients with amyotrophic lateral sclerosis during COVID-19 pandemic: an Italian ALS referral center experience R Vasta, C Moglia, F D’Ovidio, F Di Pede, F De Mattei, S Cabras, L Peotta, ... Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 22 (3-4), 308-311, 2021 | 35 | 2021 |
| A20 in multiple sclerosis and Parkinson’s disease: clue to a common dysregulation of anti-inflammatory pathways? S Perga, S Martire, F Montarolo, ND Navone, A Calvo, G Fuda, A Marchet, ... Neurotoxicity research 32 (1), 1-7, 2017 | 34 | 2017 |
| Decreased levels of foldase and chaperone proteins are associated with an early-onset amyotrophic lateral sclerosis M Filareti, S Luotti, L Pasetto, M Pignataro, K Paolella, P Messina, ... Frontiers in Molecular Neuroscience 10, 99, 2017 | 27 | 2017 |
| Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study F Faghri, F Brunn, A Dadu, A Chiò, A Calvo, C Moglia, A Canosa, ... The Lancet Digital Health 4 (5), e359-e369, 2022 | 25 | 2022 |
| Amyotrophic lateral sclerosis caregiver burden and patients’ quality of life during COVID-19 pandemic S Giusiano, L Peotta, B Iazzolino, E Mastro, M Arcari, F Palumbo, ... Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 23 (1-2), 146-148, 2022 | 19 | 2022 |
| NADPH oxidase 2 (NOX 2) enzyme activation in patients with chronic inflammatory demyelinating polyneuropathy G Marrali, P Salamone, F Casale, G Fuda, P Cugnasco, C Caorsi, ... European Journal of Neurology 23 (5), 958-963, 2016 | 16 | 2016 |
| Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double‐blind, placebo‐controlled trial E Beghi, E Pupillo, E Bianchi, V Bonetto, S Luotti, L Pasetto, C Bendotti, ... European Journal of Neurology 30 (1), 69-86, 2023 | 13 | 2023 |
| Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: the TUDCA-ALS trial protocol A Albanese, AC Ludolph, CJ McDermott, P Corcia, P Van Damme, ... Frontiers in Neurology 13, 1009113, 2022 | 11 | 2022 |
| The transcription factor Nurr1 is upregulated in amyotrophic lateral sclerosis patients and SOD1-G93A mice V Valsecchi, M Boido, F Montarolo, M Guglielmotto, S Perga, S Martire, ... Disease models & mechanisms 13 (5), dmm043513, 2020 | 10 | 2020 |
